NEW YORK — Two speakers debated whether completion lymphadenectomy is still standard of care for patients with sentinel lymph-node positive melanoma at HemOnc Today Melanoma and Cutaneous Malignancies.
Publications
Biomarker for Class 1 Uveal Melanoma Correlates with Metastatic Disease
A new biomarker measurement might improve the accuracy of prognostic testing and precision medicine in uveal melanoma, according to a study published in Clinical Cancer Research.1
Longer surgical interval shortens RFS when residual melanoma is present
NEW YORK — Longer surgical interval following initial biopsy may worsen RFS outcomes in patients with residual melanoma, according to a retrospective review presented at HemOnc Today Melanoma and Cutaneous Malignancies.
Cobimetinib in melanoma with BRAF V600 mutation: Indication of minor added benefit
Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. The Federal Joint Committee (G-BA) therefore commissioned the German Institute for Quality and Efficiency in Health Care (IQWiG) to examine whether cobimetinib in combination with vemurafenib has an added benefit over the appropriate comparator therapy vemurafenib alone.